Two-Week Radiotherapy Matches Eight-Week Course for Prostate Cancer in 10-Year Study

Results from the HYPO-RT-PC Phase III trial confirm long-term safety and efficacy of ultra-hypofractionated radiotherapy, offering a transformative option for localized prostate cancer treatment.